← Back to Search

Behavioural Intervention

Pinpoint app for Sickle Cell Disease (Pinpoint II Trial)

N/A
Waitlist Available
Led By Valerie Myers, PhD
Research Sponsored by Klein Buendel, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up final posttest (either 12-weeks or 16-weeks, per stepped wedge design)
Awards & highlights
No Placebo-Only Group

Summary

This trial tests the Pinpoint app, a game-like tool designed to help teens with sickle cell disease talk about and understand their pain. By making pain assessment fun and easy, the app aims to improve communication between teens and doctors, leading to better pain management.

Eligible Conditions
  • Sickle Cell Anemia
  • Sickle Cell Disease
  • Sickle Cell Thalassemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~final posttest (either 12-weeks or 16-weeks, per stepped wedge design)
This trial's timeline: 3 weeks for screening, Varies for treatment, and final posttest (either 12-weeks or 16-weeks, per stepped wedge design) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Sickle Cell Self-efficacy Scale
Sickle Cell Self-efficacy Scale Reported by Adolescents
Secondary study objectives
System Usability Scale (SUS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pinpoint AppExperimental Treatment1 Intervention
Tablet and smartphone application.

Find a Location

Who is running the clinical trial?

Klein Buendel, Inc.Lead Sponsor
39 Previous Clinical Trials
19,883 Total Patients Enrolled
National Institute on Minority Health and Health Disparities (NIMHD)NIH
429 Previous Clinical Trials
1,371,097 Total Patients Enrolled
Hilton Publishing CompanyUNKNOWN
1 Previous Clinical Trials
13 Total Patients Enrolled
~3 spots leftby Nov 2025